Introduction
HIV-1 can cause severe neurologic disease, including HIV-associated dementia (HAD), in a subset of infections [1, 2] . The use of highly-active antiretroviral therapy (HAART) reduces the risk for HAD [3, 4] . However, the majority of the HIV-infected population does not have access to HAART (particularly in resource poor regions), other forms of neurologic complications persist despite HAART use, and the central nervous system (CNS) may serve as an HIV-1 reservoir during HAART due to the long-lived nature of CNS-infected cells and poor penetration of certain antiretroviral therapies (ARTs) [5] [6] [7] [8] [9] . Thus, neurologic disease remains a serious complication of HIV-1 infection.
Studies [10, 11] using autopsy tissues from infected patients have demonstrated that HIV-1 genetic populations can be distinct, or compartmentalized, between the brain and periphery. However, the inability to sample HIV-1 populations directly from the brain of living individuals poses a challenge in fully understanding the dynamics of viral CNS compartmentalization over the full disease course, and ultimately its role in HIV-1 neuropathogenesis. Although HIV-1 can be sampled from cerebrospinal fluid (CSF), the use of CSF as a surrogate CNS compartment is complicated by the fact that the anatomical and cellular sources of CSF HIV-1 remain unclear. Studies [12] [13] [14] [15] have revealed that HIV-1 genetic populations in CSF and peripheral blood plasma are often compartmentalized, suggesting that at least a portion of the CSF viral population can be produced locally within the CNS.
Our group previously reported a small cross-sectional study [16] of 27 chronically infected patients that revealed elevated HIV-1 env V1/V2 compartmentalization between blood plasma and CSF in HAD participants. However, the small sample size of this initial study, including only four patients with HAD, prohibited a conclusive investigation into the relationships between CSF HIV-1 compartmentalization and broader neurologic disease. Furthermore, it is unclear whether the association between CSF HIV-1 env compartmentalization and neurologic disease is specific for the V1/V2 region. A better understanding of the dynamics of CSF HIV-1 compartmentalization throughout the full course of infection, including how it is reflected throughout the env gene, could provide additional insight into the mechanisms of HIV-1 CNS compartmentalization.
Here, we present the first systematic study that characterizes the extent of CSF HIV-1 env compartmentalization across all major clinical stages of disease, from primary infection to end-stage immune deficiency with HAD. To this end, we expanded our earlier characterizations of blood plasma/CSF HIV-1 V1/V2 compartmentalization [16, 17] , adding to the cohort for a total of 66 patients representing the major stages of HIV-1 disease and extended the genetic characterizations of env to include the V4/V5 and C2-V3 regions to enhance the measurement of compartmentalization. We found that CSF HIV-1 compartmentalization levels were comparable across all three env regions. Furthermore, the level of HIV-1 env compartmentalization between blood plasma and CSF varied considerably by disease stage. These results suggest an important role for HIV-1 env compartmentalization in the development of HAD and validate CSF HIV-1 env compartmentalization as a virus-specific biological marker of HAD that may be used to enhance future clinical studies of HIV-1 neurologic disease.
Methods

Participants
Archived human blood plasma and CSF specimens were obtained from the National NeuroAIDS Tissue Consortium and multiple clinical studies conducted at the University of North Carolina (UNC)-Chapel Hill, the HIV Neurobehavioral Research Center at the University of California, San Diego, and the University of California, San Francisco (UCSF). To limit site-specific differences in results, multiple different collection sites contributed specimens for each disease category, with the exception of primary infection (all UNC). Informed consent was obtained from all participants, and specimens were collected and used under local institutional approval. Paired blood plasma and CSF specimens were obtained at the time of neurologic diagnosis. Depending on the study site, diagnosis was based on 1991 American Academy of Neurology criteria for minor cognitive and motor disorder (MCMD) and HAD [18] , AIDS dementia complex staging [19] , or the Carey et al. [20] global impairment algorithm, or all. No primary infection patients had detectable impairment. Chronic infection patients without significant neurologic deficits were classified as 'not impaired'. Because both diagnoses have significant overlap in terms of neuropsychological pathology and less severe disease symptomology relative to HAD, data from participants diagnosed as 'Globally Impaired' or 'Minor Cognitive and Motor Disorder' (MCMD) were combined (MCMD/I).
Blood plasma and CSF viral RNA specimens from approximately 85 participants were screened for reverse transcriptase (RT)-PCR robustness and heteroduplex tracking assay (HTA) reproducibility. Results were analyzed only for participants from whom adequate viral genome amplification or template sampling was obtained (see HTA methods), which yielded env compartmentalization data from 66 total participants (Table 1) . Possible reasons for inadequate viral genome sampling for the remaining participants include low viral load, poor sample quality, or insufficient specimen volume.
Heteroduplex tracking assays
Detailed methods for viral RNA isolation, RT-PCR, and HTA are described elsewhere [21, 22] . A minimum of 100 genome templates based on viral RNA load were included in RT-PCR reactions to ensure adequate genome sampling. In addition, for most participants, viral RNA populations in blood plasma and CSF samples were analyzed in two independent RT-PCR and HTA analyses of the same env region to validate genome template sampling, based on HTA band pattern reproducibility. To limit the potentially misleading effects of poor quality genome sampling, HTA results (for a specific env region) that were not reproducible were not used. Therefore, for some participants, we used HTA results for only one region (13 participants with V1/V2 only and 10 with V4/V5 only) to quantify HIV-1 env compartmentalization. Only a single RT-PCR and HTA analysis was performed for four primary infection patients due to limited specimen volume.
Analysis of env compartmentalization
Two measures of blood plasma/CSF env compartmentalization were performed. The first, % Difference, measures the discordance of HTA band patterns in two different lanes:
where Lane#1 i is the relative abundance of a band that migrates to a particular point on the gel, i, for all bands, n, and Lane#2 i is the relative abundance of a band migrating to the same position of the gel in the other lane. For bands detected in one lane and not the other, the undetectable band was assigned a relative abundance of 0. The sum of the absolute difference for all bands was divided by 2 because an increase in abundance of one band reflects a concomitant decrease of another, and multiplied by 100 to obtain a percentage value.
A second independent measure of env compartmentalization was a bulk sequence analysis of the C2-V3 region for a subset of 54 participants. The remaining participants were not analyzed due to poor RT-PCR amplification or limited specimen volume. RNA samples were subjected to RT-PCR using primers targeting V1 (5 0 -TTATGG-GATCAAAGCCTAAAGCCATGTGTA-3 0 , HXB2 nt 6555-6584) and V3 (5 0 -TTTTGCTCTACTAATGT-TACAATGTGC-3 0 , HXB2 nt 7235-7209). The C2-V3 region (HXB2 nt 6891-7208) for each RT-PCR product was bulk sequenced using primers for each DNA strand. The highest electrophoregram peak was used for assigning bulk sequence for nucleotide positions with multiple signals (i.e., mixed sequence). Sequences have been deposited in GenBank (Accession numbers EU216434-EU216541).
Statistical analysis
Phosphorimaging data were analyzed using GraphPad Prism software (version 3.02) (GraphPad Software Inc., San Diego, California, USA). Box and whisker plots indicate the median, 25th/75th percentile, and maximum/minimum values. The nonparametric Wilcoxon rank-sum test (using Van der Waerden normal scores) was used for conservative two-group comparisons. Monte Carlo estimates of exact two-sided P-values were used. Nominal (unadjusted) P-values are shown. Univariable logistic regression was used to evaluate the relative strength of association of markers with dichotomized HAD (SAS, version 9.1, SAS Institute Inc., Cary, North Carolina, USA). As HAD is typically only diagnosed during chronic or late infection, these analyses excluded data from primary infection patients. An approximation to Bayes factors, known as the Schwartz Criterion, was used to assess the strength of each marker [23] .
Results
Study participants
Paired blood plasma and CSF specimens collected from 66 HIV-1-infected patients were analyzed for HIV-1 env compartmentalization. At the time of blood plasma/CSF sampling, participants represented cross-sections of the major clinical stages of HIV-1 infection relating to neurologic complications, from primary infection with no neurologic disease to end-stage AIDS with accompanying HAD (Table 1) . Most participants were not on ARTat the time of sampling and diagnosis, although a few in the not impaired and MCMD/I groups were on failing ART. Median plasma viral load, CSF viral load, and CD4 þ cell count values within each of these groups were not significantly different between participants off ART and on failing ART (P-values of 0.10-0.98, Wilcoxon rank-sum test), and more importantly, exclusion of participants on failing ART did not affect subsequent results of blood plasma/CSF env compartmentalization (data not shown).
Characterization of HIV-1 env variants by heteroduplex tracking assay The HTA, originally described by Delwart et al. [24, 25] , displays coexisting genetic variants present in a biological specimen as a series of distinct bands in a polyacrylamide gel. A major strength of utilizing HTA for characterizing complex HIV-1 genetic populations is the combined ability to sample hundreds of genome templates, reveal the extensive complexity of HIV-1 genetic populations in a simple assay, and validate genome template sampling by RT-PCR based on HTA band pattern reproducibility across multiple independent analyses. This makes it possible not only to compare qualitatively the genetic makeup of complex HIV-1 populations present in two different biological specimens, but also to quantify their level of similarity. Furthermore, this use of HTA to compare complex HIV-1 genetic populations can be performed on a scale that typically is not obtained through standard cloning, sequencing, and phylogenetic analysis. This allowed us to analyze a sufficient number of biological specimens (i.e. study participants) to derive generalizable conclusions and to validate the quality of sampling for each specimen to prevent misinterpretation of differences observed between blood plasma and CSF viral populations that arise as a result of sampling too few viral genomes.
HIV-1 env compartmentalization varies by disease state
We used RT-PCR and HTA to compare blood plasma and CSF HIV-1 env populations. Two different regions of env were analyzed, spanning either the V1/V2 or V4/V5 hypervariable regions. Representative HTA gels and % difference results illustrate qualitative differences in blood plasma/CSF env compartmentalization observed in different participants, as well as the reproducibility of HTA band patterns for individual replicates (Fig. 1) . To determine the relationship between env compartmentalization and HIV-associated neurologic disease, blood plasma/CSF env compartmentalization levels were measured and compared between participants at different disease stages ( Fig. 2 ). We observed clear group-specific differences in blood plasma/CSF env compartmentalization for both V1/V2 and V4/V5 HTA ( Fig. 2a ). As a control for artifactual detection of elevated env compartmentalization, RT-PCR and HTA reproducibility were shown to be similar for all groups (Fig. 2b) . Also, there was a strong correlation between V1/V2 and V4/V5 HTA measurements of blood plasma/CSF env compartmentalization ( Fig. 2a,c ), suggesting that both regions evolve differentially between the two compartments.
Our results suggest that the 'quality' of HIV-1 in CSF, reflected by blood plasma/CSF env compartmentalization, 910 AIDS 2009, Vol 23 No 8 is a strong indicator of HIV-1 neuropathogenesis contributing to HAD. Taking into account both V1/V2 and V4/V5 HTA measurements, blood plasma/CSF env compartmentalization was significantly greater in patients with HAD and significantly lower in primary infection patients, relative to the other groups tested (Fig. 2d) .
Unexpectedly, blood plasma/CSF env compartmentalization levels in chronically infected patients with less severe forms of HIV-associated neurologic disease were on average not elevated relative to non-impaired individuals. The number of HAD patients in this study (n ¼ 9) precluded a multivariable regression analysis to determine whether CSF viral load and blood plasma/CSF env compartmentalization were independent or linked markers. Nevertheless, the CSF viral load and average % difference values for patients within individual disease groups correlated only weakly or not at all (data not shown), providing preliminary evidence that CSF viral load and blood plasma/CSF env compartmentalization are independent markers of neurologic disease.
HIV-1 env C2-V3 bulk sequencing
The C2-V3 region of env is genetically less diverse relative to V1/V2 and V4/V5, but contains determinants for receptor/coreceptor binding and epitopes for neutralizing antibodies, which might play important roles in HIV-1 neurotropism [26] . We characterized env C2-V3 sequences in blood plasma and CSF from a subset of 54 participants by determining bulk sequences of the RT-PCR products and compared the sequences by phylogenetic analysis. Similar to V1/V2 and V4/V5 HTA, C2-V3 sequence analysis revealed increased levels of blood plasma/CSF env compartmentalization in HAD patients, both at the nucleotide (Fig. 3a) and protein-coding level (data not shown). Despite this result, analysis of sequences by viral epidemiology signature pattern analysis (VESPA, Los Alamos National Laboratory HIV Database) revealed no sequence signatures for CSF relative to blood plasma in HAD or non-HAD patients within the C2-V3 region. Furthermore, characterization of V3 sequence populations by HTA and sequencing for a subset of 27 participants predicted that 24/27 participants had only chemokine receptor 5 (CCR5)-utilizing variants present (one MCMD X4 and two indeterminate) and did not reveal any biased patterns of predicted coreceptor usage (data not shown).
We performed a molecular clock analysis using a well characterized reference to assess the extent of blood plasma and CSF HIV-1 env sequence divergence. Using longitudinal HIV-1 consensus sequences obtained by Shankarappa et al. [27] from eight chronically infected patients, specifically for the region overlapping the C2-V3 region analyzed here (HXB2 nt 7023-7208), we calculated [28] the rate of HIV-1 nucleotide change in the periphery for these eight patients (Fig. 3b ). This 'molecular clock' estimates that in the peripheral blood of chronically infected patients, this region of HIV-1 env evolves at a rate of 0.000692 substitutions per nucleotide site per month. Given this rate of sequence divergence, the measured mean genetic distance of 0.0295 substitutions per nucleotide site between blood plasma and CSF in HAD patients (Fig. 3a) corresponds to a time period of 57 months of HIV-1 evolution in the blood. If we assume that evolution is occurring independently and at an equal rate in each compartment, then the lineages were separated for one-half that time, or an equivalent of 28.5 months of HIV-1 evolution in the blood, compared with 6.9 and 8.8 months in non-impaired and MCMD/I patients, respectively (Table in Fig. 3b ). However, the true time of divergence of blood plasma and CSF HIV-1 populations would vary based on the rate of evolution in each compartment, which also likely varies by disease stage. Although the assumptions oversimplify the dynamics and mechanisms of HIV-1 compartmentalization, these results illustrate the remarkable degree of divergence of HIV-1 genetic populations in blood plasma and CSF of HAD patients, comparable with the genetic divergence of HIV-1 populations in the peripheral blood after nearly 5 years of untreated chronic infection.
HIV-1 compartmentalization and immune status
Neurologic disease progression to HAD typically occurs late in HIV-1 infection, usually after the onset of immune deficiency, and CD4 þ T cell counts were significantly lower in patients with HAD (Table 1) . Therefore, reduced immune selective pressure throughout all compartments, independent of neurologic disease, is Fig. 3 . Compartmentalization of the C2-V3 env bulk sequence between blood plasma and cerebrospinal fluid. (a) Genetic distances estimated from alignments of the C2-V3 consensus sequences for blood plasma and CSF using the pairwise distance function in MEGA4 [28] and specifying the Kimura 2-parameter model of nucleotide substitution to allow transition-transversion rate differences. The resulting measure of genetic distance estimates the per-site number of nucleotide substitutions, after correcting for the probability of multiple substitutions at individual sites ( Ã P < 0.01 for HAD versus MCMD/I, NI, or PI). (b) A molecular clock was determined using consensus sequences obtained from longitudinal peripheral blood mononuclear cell samplings from eight chronically infected patients, as reported by Shankarappa et al. [27] . Genetic distances for the region of sequence overlap with this study (HXB2 nt positions 7023-7208) were estimated using the Kimura two-parameter model of nucleotide substitution and represent the per-site number of nucleotide substitutions that occurred in an individual patient as the initial sample in that patient. Each color corresponds to sequences sampled from a different patient. Lines represent the best-fit linear model (solid line) and the 95% confidence limits (dashed lines). On the basis of this molecular clock, we estimated the mean time of BP/CSF env divergence for patients in different neurologic disease categories. The indicated 95% confidence interval is based on the confidence limits of the molecular clock. BP, blood plasma; CSF, cerebrospinal fluid; HAD, HIV-associated dementia; MCMD/I, minor cognitive and motor disorder/globally impaired; MEGA, molecular evolutionary genetics analysis; NI, not impaired; PI, primary infection; RT-PCR, reverse transcriptase-PCR. one possible explanation for the elevated env compartmentalization observed in HAD patients. However, we observed no correlation between CD4 þ T cell count and blood plasma/CSF env compartmentalization when analyzing results for all ( Fig. 4a ) or only HAD patients (Fig. 4b) . Furthermore, the pattern of significantly elevated blood plasma/CSF env compartmentalization in HAD patients did not change when analyzing only patients with CD4 þ T cell counts of less than 250 cells/ml (Fig. 4c) . These results suggest that immune deficiency alone, at least as reflected by CD4 þ T cell count, does not explain the increased levels of blood plasma/CSF env compartmentalization observed in patients with HAD.
Discussion
This first systematic, cross-sectional, and quantitative characterization of HIV-1 genetic compartmentalization between blood and CSF across the major stages of infection allowed us to make several specific observations about the nature of the CSF HIV-1 compartment. First, HIV-1 populations in blood and CSF are essentially indistinguishable during asymptomatic primary infection. Later during chronic infection, as the HIV-1 populations become more complex in both compartments, blood and CSF viral populations can remain well equilibrated in some patients, even in the presence of presumably strong systemic immune pressure. However, HIV-1 env populations in HAD patients, as well as some non-HAD patients in chronic infection, are highly compartmentalized between blood and CSF, suggesting a major shift in the nature of HIV-1 infection in the CSF/CNS compartment. Previous characterizations of CSF HIV-1 dynamics during HAART revealed that decay rates of bulk CSF HIV-1 viral load can vary by disease state, with significantly slower CSF HIV-1 viral load decay often observed in HAD patients [21, [29] [30] [31] . These results suggest that the primary cellular source of CSF HIV-1 changes over the disease course, which when taken together with the present study might reflect the genetic adaptation and replication of a subset of HIV-1 populations in longer lived cells in the CNS. HTA characterizations of V4/V5 populations in the present study also revealed that this region of env, similar to V1/ V2 [16] , can be highly compartmentalized between blood plasma and CSF, suggesting that the distinct selective pressures in blood plasma and CSF that are responsible for divergent env evolution in these two compartments act throughout the env gene.
Results from this study are consistent with our initial smaller scale study in supporting an important relationship between CSF HIV-1 compartmentalization and neurologic disease [16] . As in the previous study, neither overall genetic complexity in any one compartment nor the simple appearance of enriched or unique HIV-1 genetic variants in CSF correlated with neurologic disease. Rather, the overall extent of env compartmentalization, quantified by blood plasma/CSF % difference in the present study, associated best with neurologic disease. In support of these observations, a recent smallscale study revealed simian immunodeficiency virus (SIVsm) env blood plasma/CSF compartmentalization throughout the course of infection in a macaque that had significant CNS inflammation at end stage, whereas two macaques with equilibrated blood and CSF SIVsm populations throughout infection had no detectable CNS inflammation [32] . The best described genetic marker for HAD is the presence, specifically in brain tissue, of an Asn residue at amino acid coding position 283 in the env gene [33] . Although slight enrichment of N283 in CSF of HAD patients was reported [33] , we did not observe this sequence as either a marker of HAD or CSF env compartmentalization. However, there are differences in these two studies, including the use of viral DNA in autopsy brain tissue compared with viral RNA in CSF, with the brain-derived DNA representing a terminal disease state. It is also possible that env evolutionary pathways in CSF and brain are distinct, as the anatomical and cellular sources of compartmentalized and non- [34] . In this model, infected cells from both sources can contribute to a pool of viruses in CSF, but the relative contribution of the sources varies in patients on the basis of their neurologic disease state. We speculate that the level of blood and CSF HIV-1 compartmentalization is a reflection of the amount of local CNS viral replication. Accordingly, the presence of highly equilibrated blood and CSF compartments suggests that only peripheral sources contribute to the CSF HIV-1 pool, whereas a high degree of compartmentalization suggests that the predominant source of the CSF HIV-1 pool is virusproducing cells in the CNS. The level of CNS-specific viral replication could be modulated by the migration of target cells into the CNS, reduced immune surveillance, or both, but based on this model, the detection of a CSFcompartmentalized HIV-1 variant requires the presence of an autonomously replicating CNS HIV-1 subpopulation. The observed env genetic divergence of CNSspecific populations could be due to distinct selective forces on viruses at cell entry, differences in the cellular source(s) of viral populations in the CNS and periphery, reduced immune selection in the CNS, or simply founder effects, although these mechanisms are not mutually exclusive.
Our results suggest that CSF HIV-1 env compartmentalization may serve as a novel biological marker for diagnosing neurologic disease that is specifically associated with independent replication and evolution of HIV-1 in the CNS. Although the HTA methods are not likely to provide a routine clinical application in their current form, other sensitive molecular techniques may become available in the future for routine clinical use. Importantly, HIV-1 CSF compartmentalization was a robust marker of HAD but not the less severe forms of HIV-associated neurologic disease, raising the question of whether the mechanisms of MCMD are distinct from the mechanisms of HAD? One explanation is that HIV-1 compartmentalization in the CNS plays a role in MCMD, but is either not consistently reflected in CSF or was an earlier, transient event that contributed to persistent neurologic deficits. Conversely, MCMD/I, or at least a subset of such cases, might not be attributable specifically to neuropathogenesis by HIV-1. These possible explanations illustrate the importance of utilizing novel, specific, and sensitive biological markers to improve methods of research, prevention, diagnosis, and treatment of HIVassociated neurologic complications.
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